Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
Go back to Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 9.60 +0.08 (0.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.52 | 52 Week High | $82.81 | |||
| Open | $9.52 | 52 Week Low | $19.74 | |||
| Day High | $9.66 | P/E | N/A | |||
| Day Low | $9.44 | EPS | $-2.16 | |||
| Volume | 327,067 | |||||
